ReviewThe Lancet. Neurology2014
Outcome markers for clinical trials in cerebral amyloid angiopathy.
Review in The Lancet. Neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 4 syntheses or guidelines pooled it, 147 citations in OpenAlex.
- Prevalence of cerebral amyloid angiopathy: A systematic review and meta-analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Pooled it
- Cortical superficial siderosis and bleeding risk in cerebral amyloid angiopathy: A meta-analysis.Neurology · 2019Pooled it
- Pooled it
- Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: A meta-analysis.Neurology · 2018Pooled it
- Determinants of cerebral amyloid angiopathy progression: a multicenter retrospective study.Journal of neurology · 2025Article
- Enhanced Reader Confidence and Differentiation of Calcification from Cerebral Microbleed Diagnosis Using QSM Relative to SWI.Clinical neuroradiology · 2025Article
- One-Year Radiologic Progression in Sporadic and Hereditary Cerebral Amyloid Angiopathy.Neurology · 2025Article
- Cognitive Impairment in Cerebral Amyloid Angiopathy: A Single-Center Prospective Cohort Study.Journal of clinical medicine · 2024Article
- Boston Criteria v2.0 for Cerebral Amyloid Angiopathy Without Hemorrhage: An MRI-Neuropathologic Validation Study.Neurology · 2024Article
- Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy.Alzheimer's research & therapy · 2024Article
- Cerebral tau pathology in cerebral amyloid angiopathy.Brain communications · 2024Article
- Case Report: Taxifolin for neurosurgery-associated early-onset cerebral amyloid angiopathy.Frontiers in neurology · 2024Article
- Cerebral Superficial Siderosis : Etiology, Neuroradiological Features and Clinical Findings.Clinical neuroradiology · 2023Review
- Mediation of Reduced Hippocampal Volume by Cerebral Amyloid Angiopathy in Pathologically Confirmed Patients with Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2023Article
- The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study.The Lancet. Neurology · 2022Article
- Palinopsia as an initial symptom of cerebral amyloid angiopathy-related inflammation.eNeurologicalSci · 2021Article
- Review
- Decreased Basal Ganglia Volume in Cerebral Amyloid Angiopathy.Journal of stroke · 2021Article
- Vascular Risk Factors, Imaging, and Outcomes in Transient Ischemic Attack/Ischemic Stroke Patients with Neuroimaging Evidence of Probable/Possible Cerebral Amyloid Angiopathy.Oxidative medicine and cellular longevity · 2021Article
- Vascular amyloid accumulation alters the gabaergic synapse and induces hyperactivity in a model of cerebral amyloid angiopathy.Aging cell · 2020Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 11 institutions in 6 countries.
Funding
Abstract
Efforts are underway for early-phase trials of candidate treatments for cerebral amyloid angiopathy, an untreatable cause of haemorrhagic stroke and vascular cognitive impairment. A major barrier to these trials is the absence of consensus on measurement of treatment effectiveness. A range of potential outcome markers for cerebral amyloid angiopathy can be measured against the ideal criteria of being clinically meaningful, closely representative of biological progression, efficient for small or short trials, reliably measurable, and cost effective. In practice, outcomes tend either to have high clinical salience but low statistical efficiency, and thus more applicability for late-phase studies, or greater statistical efficiency but more limited clinical meaning. The most statistically efficient markers might be those that are potentially reversible with treatment, although their clinical significance remains unproven. Many of the candidate outcomes for cerebral amyloid angiopathy trials are probably applicable also to other small-vessel brain diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.